## **AMENDMENTS TO THE CLAIMS**

- **1. (Original)** An agent for treating chondroma and chondrosarcoma comprising a substance which inhibits binding of parathyroid hormone related peptide to a receptor thereof.
- **2.** (Original) The agent according to Claim 1, wherein the substance is an antagonist of the parathyroid hormone related peptide receptor.
- **3. (Original)** The agent according to Claim 1, wherein the substance is an antiparathyroid hormone related peptide antibody.
- **4.** (Original) The agent according to Claim 1, wherein the substance is a fragment and/or a modified antibody of an anti-parathyroid hormone related peptide antibody.
- **5.** (Currently amended) The agent according to Claim 3 or 4, wherein the antibody is a monoclonal antibody.
- **6.** (Currently amended) The agent according to Claim 3 or 4, wherein the antibody is a humanized or chimerized antibody.
- **7.** (**Original**) The agent according to Claim 6, wherein the humanized antibody is a humanized #23-57-137-1 antibody.
- **8.** (Original) A method of inducing apoptosis in chondroma and chondrosarcoma cells by administering a substance which inhibits binding of parathyroid hormone related peptide and a receptor thereof.
- **9.** (**Original**) The method according to Claim 8, wherein the substance is an antiparathyroid hormone related peptide antibody.